Ambler, PA, November 01, 2017 --(PR.com
)-- MBF Therapeutics, Inc., a clinical stage animal health company developing checkpoint inhibitor vaccines for cancer and infectious diseases, today announced that Thomas Tillett, Chief Executive Officer, will present at the PACT Capital Conference in Philadelphia, PA on Thursday, November 2, 2017 at 9:45am EDT.
To access a copy of the presentation, please visit MBFT’s News section at www.mbftherapeutics.com.
About MBF Therapeutics, Inc.:
MBFT is a clinical-stage animal health company developing and commercializing proprietary checkpoint inhibitor immunotherapy (CPII) technology based on vaccines and vaccine adjuvants exclusively licensed from the Wistar Institute in Philadelphia PA. This is a platform technology from which multiple innovative products can be developed for markets worth more than $5BM.
Our lead product is MBFT-201, a canine melanoma vaccine for dogs with Stage II/III resectable disease. We have completed a Phase I study that demonstrated the safety of our adenoviral vectored product and elicited a strong immune response to key antigens in 100% of the dogs treated.